Fedratinib
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Ruxolitinib is the only JAK2 inhibitor approved for myelofibrosis (MF). Although JAK2 inhibitor therapy improves splenomegaly and…
Methods of treating vitiligo using JAK/STAT modulating compounds are provided herein. The JAK/STAT modulating compounds may be…
In the above article [Giacomini MM, Hao J, Liang X, Chandrasekhar J, Twelves J, Whitney JA, Lepist E-I, and Ray AS (2017) Drug…
119 The US Food and Drug Administration put a clinical hold on all trials of Sanofi’s fedratinib, a highly selective JAK2…